✓
Open
20 Dec 2024
✓
Close
24 Dec 2024
3
Allotment
—
✓
Listing
Mon, Dec 30, 2024
Price Band
₹372 to ₹391
Issue Size
1,48,87,723 shares (agg. up to ₹582 Cr)
Lot Size
38 Shares
Listing Date
Mon, Dec 30, 2024
Latest GMP
₹284
Est. Gain
72.63%
✦ AI Insight
GMP Trend
30-12-2024₹284Est. ₹675+72.63%
29-12-2024₹284Est. ₹675+72.63%
28-12-2024₹284Est. ₹675+72.63%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 54.02x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| NET Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,647.10 |
| Akums Drugs & Pharmaceuticals Ltd. | Mainboard | ₹1,856.74 Cr | ₹679 | null | ₹796.25 | +17.27% | ₹736.60 |
| Emcure Pharmaceuticals Ltd. | Mainboard | ₹1,952.03 Cr | ₹1008 | 34.55 | ₹1,359.15 | +34.84% | ₹1,925.80 |
| Innova Captab Ltd. | Mainboard | ₹570.00 Cr | ₹448 | 31.64 | ₹541.40 | +20.85% | ₹1,171.80 |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹37.55 |
| Medicamen Organics Ltd. | SME | ₹10.54 Cr | ₹34 | 30.53 | ₹144.70 | +325.59% | ₹26.50 |
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹82.00 |
| Zenith Drugs Ltd. | SME | ₹40.68 Cr | ₹79 | 18.4 | ₹105.15 | +33.10% | ₹48.85 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | 107.00 |
| 2 | Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company | 73.48 |
| 3 | Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | 20.22 |
| 4 | Funding the working capital requirements of the Company | 43.26 |
| 5 | Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements | 59.48 |
| 6 | Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes | 154.37 |
About Senores Pharmaceuticals IPO
Updated on Aug 5, 2026
Contact Details
Senores Pharmaceuticals Ltd. Address1101 to 1103, 11th floorSouth Tower, ONE 42 oppositeJayantilal ParkAmbali Bopal RoadAhmedabad, Gujarat, 380054+91-79-29999857cs@senorespharma.comVisit Website